T. Rowe Price Health Sciences Fund PRHSX

Morningstar Medalist Rating
  • NAV / 1-Day Return$102.21  /  0.00
  • Fund Size$12.9B
  • Adjusted Expense Ratio0.830%
  • Net Expense Ratio0.830%
  • Fee Level: DistributionBelow Average
  • Share Class TypeNo Load
  • Morningstar CategoryHealth
  • Equity Style Box (Funds)Large Value
  • Minimum Initial Investment$2,500
  • Investment StatusOpen
  • TTM Yield0.10%
  • Turnover Ratio62%

Morningstar’s Analysis PRHSX

Will PRHSX outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

A leadership change tests a proven process.

Associate Analyst Natalia Arrigoni

Natalia Arrigoni

Associate Analyst

Summary

An impending lead-manager change creates uncertainty for this otherwise strong healthcare strategy, prompting a downgrade of the People Pillar to Average from Above Average. Longtime lead manager Ziad Bakri announced in December 2025 that he will leave T. Rowe Price in July 2026 after a decade at the helm. His departure is certainly a loss, but incoming lead manager Jeff Holford knows the process well and plans to stick with it, supporting the decision to maintain an Above Average Process rating.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings PRHSX

  • Current Portfolio Date
  • Equity Holdings—
  • Bond Holdings—
  • Other Holdings—
  • % Assets in Top 10 Holdings54.8
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

13.042B
Healthcare

Aggregate Miscellaneous Equity

7.68940M
—

Johnson & Johnson

6.75826M
Healthcare

Merck & Co Inc

5.49672M
Healthcare

UnitedHealth Group Inc

5.41663M
Healthcare

AbbVie Inc

5.41662M
Healthcare

Thermo Fisher Scientific Inc

3.26400M
Healthcare

Gilead Sciences Inc

2.99366M
Healthcare

Amgen Inc

2.43298M
Healthcare

Abbott Laboratories

2.32284M
Healthcare

Sponsor Center